Total Payments
$79,840
2024 Payments
$1,524
Companies
40
Transactions
650
Medicare Patients
1,651
Medicare Billing
$153,612
Payment Breakdown by Category
Research$69,848 (87.5%)
Food & Beverage$9,981 (12.5%)
Education$11.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $69,848 | 4 | 87.5% |
| Food and Beverage | $9,981 | 644 | 12.5% |
| Education | $11.00 | 2 | 0.0% |
Payments by Type
Research
$69,848
4 transactions
General
$9,992
646 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $69,848 | 4 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $1,866 | 89 | $0 (2024) |
| Novo Nordisk Inc | $1,608 | 120 | $0 (2024) |
| Lilly USA, LLC | $814.12 | 56 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $716.38 | 49 | $0 (2024) |
| Endo Pharmaceuticals Inc. | $566.13 | 56 | $0 (2022) |
| Astellas Pharma US Inc | $528.09 | 36 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $419.16 | 22 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $391.09 | 23 | $0 (2024) |
| Amgen Inc. | $350.12 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,524 | 81 | AstraZeneca Pharmaceuticals LP ($425.13) |
| 2023 | $1,492 | 94 | AstraZeneca Pharmaceuticals LP ($179.67) |
| 2022 | $1,406 | 84 | Novo Nordisk Inc ($343.95) |
| 2021 | $16,180 | 102 | Eli Lilly and Company ($14,713) |
| 2020 | $55,954 | 58 | Eli Lilly and Company ($55,135) |
| 2019 | $1,160 | 86 | Novo Nordisk Inc ($245.19) |
| 2018 | $1,085 | 87 | AstraZeneca Pharmaceuticals LP ($334.50) |
| 2017 | $1,038 | 58 | AstraZeneca Pharmaceuticals LP ($200.68) |
All Payment Transactions
650 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/16/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: UROLOGY | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Gastroenterology | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: RESPIRATORY | ||||||
| 11/26/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: UROLOGY | ||||||
| 11/25/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/13/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $7.43 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $11.52 | General |
| Category: Diabetes | ||||||
| 10/29/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $12.26 | General |
| Category: UROLOGY | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: RESPIRATORY | ||||||
| 10/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Gastroenterology | ||||||
| 10/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Diabetes Care | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $32.82 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/03/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: UROLOGY | ||||||
| 10/02/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $29.48 | General |
| Category: Diabetes | ||||||
| 10/01/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: Cardio-renal | ||||||
| 09/23/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: ENDOCRINOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $68,678 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $1,170 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 349 | 577 | $245,086 | $34,052 |
| 2022 | 8 | 343 | 574 | $257,595 | $30,187 |
| 2021 | 15 | 664 | 1,188 | $316,893 | $54,920 |
| 2020 | 8 | 295 | 579 | $255,394 | $34,454 |
Total Patients
1,651
Total Services
2,918
Medicare Billing
$153,612
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 66 | 240 | $161,520 | $19,130 | 11.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 44 | 44 | $30,184 | $5,615 | 18.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 33 | 68 | $14,620 | $3,280 | 22.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 40 | $18,960 | $1,980 | 10.4% |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 2023 | 34 | 35 | $6,720 | $1,646 | 24.5% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 22 | 22 | $4,378 | $839.67 | 19.2% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 47 | 47 | $2,310 | $615.59 | 26.6% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 44 | 44 | $2,170 | $578.28 | 26.6% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 23 | 24 | $4,224 | $368.45 | 8.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Office | 2023 | 13 | 13 | $0.13 | $0.13 | 100.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 79 | 222 | $149,406 | $17,011 | 11.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 44 | 44 | $30,184 | $5,928 | 19.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 77 | 127 | $60,198 | $5,636 | 9.4% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 17 | 17 | $8,244 | $625.38 | 7.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 16 | 53 | $3,869 | $563.50 | 14.6% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 16 | 17 | $5,693 | $421.32 | 7.4% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 51 | 51 | $0.51 | $0.51 | 100.0% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 43 | 43 | $0.43 | $0.43 | 100.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 142 | 327 | $171,405 | $29,375 | 17.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 172 | 280 | $103,838 | $15,480 | 14.9% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 69 | 70 | $3,850 | $2,555 | 66.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 18 | 18 | $9,600 | $2,506 | 26.1% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 45 | 45 | $3,375 | $1,831 | 54.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $8,272 | $1,136 | 13.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 11 | 11 | $5,856 | $543.18 | 9.3% |
About Dr. Victor Escobar, M.D
Dr. Victor Escobar, M.D is a Family Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/07/2012. The National Provider Identifier (NPI) number assigned to this provider is 1184983496.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Victor Escobar, M.D has received a total of $79,840 in payments from pharmaceutical and medical device companies, with $1,524 received in 2024. These payments were reported across 650 transactions from 40 companies. The most common payment nature is "" ($69,848).
As a Medicare-enrolled provider, Escobar has provided services to 1,651 Medicare beneficiaries, totaling 2,918 services with total Medicare billing of $153,612. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Houston, TX
- Active Since 05/07/2012
- Last Updated 02/10/2016
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1184983496
Products in Payments
- FARXIGA (Drug) $1,196
- Ozempic (Drug) $932.09
- XARELTO (Drug) $680.03
- NASCOBAL (Drug) $566.13
- JARDIANCE (Drug) $465.04
- Kerendia (Drug) $419.16
- ZENPEP (Drug) $388.11
- XIFAXAN (Drug) $286.71
- Rybelsus (Drug) $273.24
- BYDUREON (Drug) $248.55
- AIRSUPRA (Drug) $241.46
- MOUNJARO (Drug) $222.95
- EVENITY (Biological) $219.15
- TRULICITY (Drug) $217.96
- Vascepa (Drug) $215.26
- GEMTESA (Drug) $214.92
- CREON (Drug) $185.87
- Myrbetriq (Drug) $177.61
- VESICARE (Drug) $169.11
- JANUVIA (Drug) $133.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Houston
Shannon Schrader, Md, MD
Family Medicine — Payments: $383,042
Family Medicine $383,042
Dr. Eric Nolen, Md, Mba, MD, MBA
Family Medicine — Payments: $158,026
Family Medicine $158,026
Candice Winful, M.d, M.D
Family Medicine — Payments: $123,290
Family Medicine $123,290
Dr. Joe Pouzar, M.d, M.D
Family Medicine — Payments: $104,957
Family Medicine $104,957
Dr. Oscar De Valle, M.d, M.D
Family Medicine — Payments: $78,226
Family Medicine $78,226
Ms. Guljeet Sohal, M.d, M.D
Family Medicine — Payments: $72,886
Family Medicine $72,886